

**How to cite this article:**

- Calvo-Salazar RA, David M, Zapata-Mesa MI, Rodríguez-Naranjo CM, Valencia-Acosta NY. Drug-related problems causing hospital admissions in the emergency rooms at of high complexity hospital.
- Farm Hosp. 2018;42(6):228-233.



ORIGINALS

Bilingual edition English/Spanish

**Drug-related problems causing hospital admissions in the emergency rooms at of high complexity hospital**

**Problemas relacionados con medicamentos que causan ingresos por urgencias en un hospital de alta complejidad**

Rosa Alexandra Calvo-Salazar<sup>1</sup>, Maribel David<sup>2</sup>, Martha Isabel Zapata-Mesa<sup>1</sup>, Carolina María Rodríguez-Naranjo<sup>1</sup>, Naira Yadira Valencia-Acosta<sup>1,3</sup>

<sup>1</sup>Pharmacovigilance, Hospital Universitario San Vicente Fundación, Medellín. Colombia. <sup>2</sup>Pharmacovigilance Resident, Hospital Universitario San Vicente Fundación, Medellín. Colombia. <sup>3</sup>School of Pharmaceutical and Nutritional Sciences, Universidad de Antioquia. Colombia.

**Author of correspondence**

Rosa Alexandra Calvo-Salazar  
Calle 64 n.º 51D - 154, Bloque 10.  
Medellín, Colombia

Email:

racs@sanvicentefundacion.com

Recibido el 26 de febrero de 2018;  
aceptado el 30 de junio de 2018.

DOI: 10.7399/fh.10996

**Abstract**

**Objective:** Determining hospital admissions prevalence associated with problems related to medicines in the emergency services of high complexity hospital; performing the pertinent pharmaceutical interventions.

**Method:** Descriptive observational cross-sectional study. The medical records of the patients admitted to the emergency services were reviewed. Those that reported hospitalization due to problems related to medication were selected. These were classified according to the Third Consensus of Granada adaptation. A pharma-therapeutic profile was made to hospitalized patients; performing the necessary pharmaceutical interventions to avoid future medication related problems.

**Results:** 3.8% of patients were included in the study. The problems related to medications had a preventability of 87.7% and the most frequent were those of need with 42.2%. A pharma-therapeutic profile was done to hospitalized patients (137). 150 pharmaceutical interventions were done, which had an acceptance of 95.3%. The most intervened risk was administering an unnecessary medication 62.7%.

**Conclusions:** Lack of supervision and analysis of problems related to medication could cause therapeutic approach failure, therefore, health and life quality improvement of the patients is not achieve. The pharmaceutical chemist plays a fundamental role in the health care of patients, helping to the prevention and proper use of medicines. The Pharmaceutical Care program proves that it provides an invaluable contribution to public health service by improving the pharmacological safety of treatments, reducing costs and public health problems.

**Resumen**

**Objetivo:** Determinar la prevalencia de ingresos hospitalarios asociados a problemas relacionados con medicamentos en los servicios de urgencias de un hospital de alta complejidad, realizando las intervenciones farmacéuticas pertinentes.

**Método:** Estudio observacional descriptivo de corte transversal. Se revisaron las historias clínicas de pacientes que ingresaron en los servicios de urgencias, seleccionando aquellas que reportaban ingresos por problemas relacionados con medicamentos. Estas se clasificaron según la adaptación del Tercer Consenso de Granada. Se realizó un perfil farmacoterapéutico a los pacientes hospitalizados y se establecieron las intervenciones farmacéuticas necesarias para evitar futuros problemas relacionados con medicamentos.

**Resultados:** El 3,8% de los pacientes fueron incluidos en el estudio. Los problemas relacionados con medicamentos tuvieron una evitabilidad del 87,7% y los más frecuentes fueron los de necesidad, con un 42,2%. Se realizó un perfil farmacoterapéutico a los pacientes hospitalizados (137) y se llevaron a cabo 150 intervenciones farmacéuticas, las cuales fueron aceptadas en un 95,3%. El riesgo más intervenido fue administrar un medicamento innecesario (62,7%).

**Conclusiones:** La falta de supervisión y análisis de problemas relacionados con los medicamentos podría ocasionar el fracaso del abordaje terapéutico y la no consecución de la mejoría de la salud y la calidad de vida de los pacientes. El químico farmacéutico cumple un papel fundamental en el cuidado de la salud de los pacientes, ayudando desde la prevención y el uso adecuado de los medicamentos. El programa de Atención Farmacéutica demuestra que brinda un aporte inestimable al servicio de la salud pública al mejorar la farmacoseguridad de los tratamientos, disminuyendo costes y problemas de salud pública.

**KEYWORDS**

Medication errors; Pharmaceutical care; Public health.

**PALABRAS CLAVE**

Atención farmacéutica; Errores de medicación; Salud pública.



Los artículos publicados en esta revista se distribuyen con la licencia  
Articles published in this journal are licensed with a  
Creative Commons Attribution 4.0  
<https://creativecommons.org/licenses/by-nc-nd/4.0/>  
La revista Farmacia no cobra tasas por el envío de trabajos,  
ni tampoco por la publicación de sus artículos.

## Introduction

Even though medications are used to prevent, diagnose and treat diseases, their use can produce health problems, called drug-related problems (DRPs): "any undesirable event experienced by a patient that involves, or is suspected to involve, drug therapy, and that interferes or could potentially interfere with achieving the desired goals for the patient"<sup>1</sup>. A DRP can be the cause of treatment failure, and can even trigger new medical problems, more complex than the disease that was being initially treated<sup>2</sup>.

Pharmacotherapy-associated morbidity represents a serious public health problem, because it leads to a high demand of healthcare services, and this entails major healthcare expenses, determined by an increase in hospital stay; it is one of the main causes of death in developed countries<sup>3</sup>, above diabetes and pneumonia.

In the American health system, 0.8 US\$ per dollar spent on medications are used to repair the damage caused by a medication<sup>4</sup>. Medication-related errors cause at least 1 death per day, and damages to approximately 1.3 million persons per year<sup>5</sup>.

In Colombia, according to the Pharmacovigilance Report by the National Institute for Drugs and Food Vigilance (*Instituto Nacional de Vigilancia de Medicamentos y Alimentos*, INVIMA), 12,066 DRP reports were processed during the first two months of 2017<sup>6</sup>.

Based on this, and considering that the essential basis for the concept of pharmaceutical care assigns new responsibilities to Pharmacists regarding patients, and having as final clinical objective the prevention of morbidity and mortality caused by medications, through a pharmaceutical practice targeted to ensuring an adequate pharmacotherapy, which is safe and effective for all patients<sup>5</sup>, the objective of this study was to determine the prevalence of hospital admissions associated with DRPs in the Emergency Unit of the *Hospital Universitario San Vicente Fundación* (HUSVF) and to conduct any relevant Pharmaceutical Interventions (PIs).

## Methods

An observational descriptive cross-sectional study, associated with the treatment of patients who attended the Emergency Unit of the HUSVF due to DRPs between February and April, 2017. DRPs were classified according to the Third Consensus of Granada on DRPs<sup>1</sup>, and its adaptation according to the Pharmacovigilance Protocol of the institution<sup>7</sup>.

There was a daily review of the clinical records of all patients admitted to the Emergency Unit of the HUSVF on the day before, including patients of all age groups. The tool used for data collection was a database designed in Office Excel<sup>®</sup>, where the epidemiological data from the clinical records were recorded. There was an analysis of the pharmacotherapeutic profile of those patients who were hospitalized. The patient or their relatives were interviewed, in order to obtain more information about their health problem.

According to the information obtained, PIs were conducted in order to achieve the desired therapeutic objective, thus reducing any undesirable effects and increasing the benefits of the medication administered. The most relevant PIs were recorded in the clinical record of the patient.

PIs were adjusted to the institutional program, and were targeted to the healthcare staff, the patient, or the relevant EPS (Health Promotion Company), in order to prevent any future DRPs. They were classified as follows:

1. **Clinical Interventions:** Adequate dose, relevance of the use of the medication, drug-drug interactions, administration schedule, and adequate recommendations for patients regarding administration.
2. **Technical Interventions:** Incompatibilities in "Y".
3. **Administrative Interventions:** Actions targeted to the administrative management of the medication with the EPS.

The education for patients and relatives regarding the adequate use of medications was not taken into account as a type of intervention, because it would be difficult to measure it quantitatively as a variable within the study; besides, there would not be enough time to include the patient load. However, during the interviews with patients in order to achieve other types of interventions, they were always orientated about their adequate use. The healthcare staff also provided education,

in addition to the patient education groups available in the hospital for specific conditions.

Data processing was conducted through the SPSS statistical package, version 24.0.

This project was approved by the Ethics Committee of the HUSVF.

## Results

There was a review of 21,424 clinical records between 14<sup>th</sup> February, and 30<sup>th</sup> April, 2017, of patients admitted through the Emergency Unit of the HUSVF; of these, 822 patients had a DRP as cause for admission, with a 3.8% prevalence. The mean hospital stay of these patients was 4.6 days; 719 (87.5%) of patients had < 10 days of stay, and the most frequent range was 0-1 days with 374 patients (45.5%).

Their sociodemographical and clinical characteristics appear in table 1.

Table 2 is a classification of DRPs according to the adaptation of the Third Consensus of Granada. The category with the highest frequency reported was need, with 346 admissions (42.1%); followed by the efficacy category, with 311 admissions (37.8%). And within the safety category, adverse reactions to medications (ARMs) stood out with 98 admissions (11.9%). There were 12 undesired drug interactions, representing 1.5% of the total DRPs.

The pharmacological group with the highest proportion of association with DRPs was psychotropic drugs, with 137 cases (16.7%), followed by drugs for hypertension, with 105 cases (12.8%). Of the total DRP cases, the neurological system was the most affected, with 208 cases (25.3%), and 198 of these could have been prevented; followed by the cardiovascular system, with 132 cases (16.0%), of which 723 cases (87.7%) could have been prevented.

Of the 822 patients included in the study, a pharmacotherapeutic profile was conducted to those 138 (16.8%) that were hospitalized; the remaining 684 (83.2%) were excluded from the PI analysis, and 288 of these patients excluded received education by the nursing staff about the DRP that led them to the Emergency Unit. At least one PI was conducted for 137 patients with a pharmacotherapeutic profile. In total, 150 PIs were conducted: 68 were clinical (45.3%), 1 was technical (0.7%) and 81 were administrative (54%). It was impossible to conduct one administrative PI because the patient because the patient did not have EPS to report the case to.

There was a 95.3% proportion of PI acceptance. Figure 1 shows the risks object of interventions in all patients with PI, as well as the lesion prevented in those cases where the PI was accepted.

## Discussion

Some studies have been conducted in recent years, with the aim to assess the prevalence of DRPs in patients admitted through the Emergency Units; these studies have reported a prevalence between 1.0% and 33.1%<sup>9,11</sup>; in the present study, the prevalence was 3.8%. Anyway, these data are difficult to compare, because the time of the studies, their methodology and the way to classify DRPs are different in each center; however, it is evident that these are problems that require an intervention, as they have a direct and negative impact on public health.

Moreover, 822 DRPs were found, that is to say, 274 DRPs/month, compared with other studies with 71 DRPs/month<sup>11</sup>, 43 DRPs/month and 404.9 DRPs/month<sup>12</sup>, but over longer periods of time, which demonstrated the efficacy in the identification of the problem under study.

The highest percentage of DRPs appeared in women, and this is consistent in different studies; this fact can be associated with a higher intrinsic sensitivity to adverse reactions in this gender<sup>9,11,13,14</sup>.

When analyzing the frequency of DRPs according to age, the higher percentage was found in the age range between 18 and 59-year old (46.5%), and the group with the lowest percentage was represented by persons between 0 and 1 years of age (1.9%). Some articles have reported a higher frequency of DRPs in patients > 60-year-old<sup>15</sup>; in this study we have observed a high percentage of 32.2%, but it is not the group with the highest incidence, and this shows that age is not a determining factor for the presence of DRPs.

**Table 1.** Sociodemographical and clinical characteristics of patients admitted at the Emergency Unit of the HUSVF due to a DRP between February and April, 2017

Characteristics	Frequency	Percentage	
Gender	Female	441	53.65
	Male	381	46.35
Age range	Adult: 18-to-59-year-old	382	46.47
	Elderly adult: ≥ 60-year-old	265	32.24
	Child: 1-to-12-year-old	99	12.04
	Adolescent: 13-to-17-year-old	60	7.30
	Infant: < 1-year-old	16	1.95
Marital Status	Single	420	51.09
	Married	133	16.18
	No data	106	12.90
	Widow/widower	57	6.93
	Consensual union	55	6.69
	Separated	33	4.01
	N/A	12	1.46
	Divorced	6	0.73
Occupation	Homemaker	186	22.63
	No data	180	21.90
	Employee	137	16.67
	Student	103	12.53
	N/A	86	10.46
	Retired	50	6.08
	Mixed occupation	38	4.62
	Unemployed	26	3.16
	Traveling salesperson	16	1.95
Place of residence	Urban	687	83.58
	No data	100	12.17
	Rural	35	4.26
Family support	Yes	692	84.18
	N/A	66	8.03
	No	64	7.79
Type of affiliation	Subsidized*	412	50.12
	Contributive*	353	42.94
	No data	57	6.93
Smoking status	Non-smoker	328	39.90
	No data	265	32.24
	Ex-smoker	100	12.17
	Active smoker	100	12.17
	Passive smoker	29	3.53
Use of alcohol	No	369	44.89
	No data	255	31.02
	N/A	106	12.90
	Yes	92	11.19
Adherence to pharmacological treatment	Yes	427	51.95
	No	296	36.01
	N/A	99	12.04
Number of medications per patient	1	346	42.09
	2 to 3	298	36.25
	4 to 5	120	14.60
	≥ 6	58	7.06

**No data:** This information was not available in the clinical record. **\* Contributive regimen:** Including those persons affiliated through a work contract, public servants, retired persons and pensioners, and independent workers with the ability to pay. **Subsidized regimen:** Persons without the ability to pay and cover the total amount of the contribution<sup>8</sup>. N/A: Not applicable.

Drug-related problems causing hospital admissions in the emergency rooms at of high complexity hospital

Some authors suggest that polymedication is one of the causes for the presence of DRPs<sup>16,17</sup>; in this study, we found that the highest percentage of patients were only with 1 medication, which showed that risk is not associated to the number of medications that a patient might be taking, but to the effect associated to each of them.

In some studies, the DRP classification with the highest incidence was efficacy<sup>18,19</sup>, while in our study, the DRP with the highest percentage was need; the reason for this was that the EPS did not provide patients with the medications required for treating their conditions, or it did not supply their complete treatment.

The percentage of undesired drug interactions was 1.5% of the total DRPs; some articles reported 33.0%<sup>20</sup>; the concern about this piece of data is that all interactions can be prevented, and this demonstrates once again that drug interactions present a high risk for patients, and that in most cases they are not taken into account in clinical practice.


The neurological system was the most affected; this was not reported as one of the most affected systems in the bibliography reviewed. The cardiovascular system was the second most affected, and this is consistent with the reports from another study<sup>18</sup>; therefore, it is highly important that those persons

on treatment with these medications undergo a more frequent medical monitoring.

The percentage of avoidable DPRs was above the one reported by some studies, determining as avoidable up to 73.0%<sup>19</sup>. This result is very important, because it shows that this figure can be reduced by improving the weak points associated with medications, such as dispensing and treatment adherence.

The percentage of accepted interventions in our study was 95.3%, similar to those recorded in the majority of studies (84.0-99.0%)<sup>19,21</sup>; it is worth highlighting that other studies reported an acceptance rate of 41.7%<sup>12</sup> and 2.8%<sup>22</sup>. The acceptance of PIs has an impact on patient health, because there is a reduction in the risk of adverse effects, and this helps to improve the adherence to pharmacological treatment.

They most relevant type of intervention was the one classified as administrative, with 54.0%; this was caused by patients not receiving their medications by the Pharmacy Unit, or delays in their authorization by their respective EPS, a situation consistent with the crisis in the health sector currently occurring in this country. Clinical interventions should also be pointed out, associated with administration time, which targeted the nursing staff (20.7%), and the relevance of this in terms of patient care.



**Figure 1.** Risk intervened and lesion prevented with the PI program in patients with DRPs from the Emergency Units of the HUSVF between February and April, 2017.

**Table 2.** Drug-related problems and their causes that led to admission at the Emergency Unit of the HUSVF between February and April, 2017

Category	Classification	Potential cause	N	(%)	
Need	DRP 1: The patient suffers a health problem as a consequence of not receiving a medication they need	Availability	1.1. Lack of the medication in the Pharmacy Unit, which leads to incomplete dispensing or not providing the medications in the amount, concentration, and formulation prescribed by the physician	50	6.1
		Dispensing	1.2. Associated with the order or dispatch	42	5.1
		Prescription	1.3. Not prescribed by the treating physician	41	5.0
	DRP 2: The patient suffers a health problem as a consequence of receiving a medication they don't need.	Administration	1.4. A medication prescribed is not administered	0	0.0
		Use	1.5. Non-compliance by the patient	213	25.9
		Prescription	2.1. The treating physician prescribes a medication not needed	0	0.0
Efficacy	DRP 3: The patient suffers a health problem as a consequence of a non-quantitative lack of efficacy of the medication	Administration	2.2. A medication not prescribed is administered	0	0.0
		Prescription	3.1. Antagonistic drug interaction	5	0.6
			3.2. Existence of a more effective medication (according to the risk-benefit ratio)	144	17.5
	DRP 4: The patient suffers a health problem as a consequence of a quantitative lack of efficacy of the medication	Quality	3.3. Lower concentration of the active principle (treatment failure)	5	0.6
		Prescription	4.1. Dosing, frequency and length of treatment	114	13.9
		Administration	4.2. Length, frequency, dilution, dosing, and way of administration	43	5.2
Safety	DRP 5: The patient suffers a health problem as a consequence of a non-quantitative lack of safety of the medication	ADR	5.1. Idiosyncratic adverse reaction	98	11.9
		Prescription	5.2. Presence of contraindications	0	0.0
			5.3. Synergic pharmacological interaction	7	0.9
		Quality	5.4. Contamination, excipients and vehicles	0	0.0
	DRP 6: The patient suffers a health problem as a consequence of a quantitative lack of safety of the medication	Prescription	6.1. Dosing, frequency and length of treatment	15	1.8
		Administration	6.2. Length, frequency, dilution, dosing, and way of administration	45	5.5

ADR: adverse reactions to medications; DRP: drug-related problems.

The risk prevented with pharmaceutical interventions by 62.7% was the unnecessary administration of a drug, followed by the risk of Lack of adherence to pharmacological treatment, with 20.7%; this result was not found in the studies reviewed, and we consider it to be highly important, because cross-sectional-type actions can be generated to reduce this risk in health centers.

The hospital stay for the majority of patients was < 10 days, and the most frequent was 0-1 days (45.5%); this is very similar to the 7 days of hospital stay reported by other articles<sup>23</sup>, which represents high costs for the public health setting; and a great proportion of these could have been prevented by conducting a pharmacotherapeutic follow-up of patients.

When analyzing DRP severity, 14 of the 822 patients included in the study had a fatal outcome, and DRPs were a factor contributing to the death of these patients. This result was not analyzed in the studies with which this study was compared, and it is highly relevant, because it shows that a bad use of medications leads to fatal outcomes.

The conclusion is that the lack of consideration and analysis of DRPs could lead to a failure of the therapeutic approach, and therefore to the failure in the search for an improvement in health and quality of life. There are different strategies for implementing patient safety from the perspective of medication. The pharmacist plays an essential role in patient healthcare, helping with the prevention and adequate use of medications. There is an increasing need to integrate this professional

group into multifactorial healthcare, in order to contribute directly not only to a scientific and rational use of medications, but also in terms of working as part of this team for the comprehensive health of patients. The PI program has demonstrated to offer an invaluable contribution to the public health system, by improving drug safety in treatments, and reducing costs and problems in public health.

## Funding

No funding.

## Acknowledgements

To the Pharmacovigilance Unit, managers, and staff of the *Hospital Universitario San Vicente Fundación*, for their help and support.

## Conflict of interests

No conflict of interests.

## Contribution to the scientific literature

Many hospital admissions due to DRP could be prevented. PIs improved treatment safety, and prevented complications.

## Bibliography

1. Grupo de Investigación en Atención Farmacéutica. Universidad de Granada; Grupo de Investigación en Farmacología. Universidad de Granada; Fundación Pharmaceutical Care (España); Sociedad Española de Farmacia Comunitaria (SEFaC). Tercer consenso de Granada sobre problemas relacionados con medicamentos (PRM) y resultados negativos asociados a la medicación (RNM). *Ars Pharm.* 2007;48(1):5-17.
2. Visconti JA, Smith MC. The Economics of Adverse Drug Reactions—Case Studies. *Ann Pharmacother* [Internet]. 2006 [accessed 13/8/2017];40(3):529-36. Available at: <http://journals.sagepub.com/doi/10.1345/aph.140011>
3. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen L, *et al*. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. *JAMA* [Internet]. 2011 [accessed 13/8/2017];277(4):307-11. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9002493>
4. Bignone MA, Schiaffino S. Manual de Buenas Prácticas de Farmacovigilancia. Buenos Aires. Programa 75 Aniversario de Gador SA, 1940-2015; 2016. 415 p.
5. Dader MJF, Romero FM. La atención farmacéutica en farmacia comunitaria: evolución de conceptos, necesidades de formación, modalidades y estrategias para su puesta en marcha. *Pharm Care Esp.* 1999;1:52-61.
6. Farma Seguridad. 2017 [accessed 13/8/2017];6(1). Available at: [https://www.invima.gov.co/images/pdf/farmacovigilancia\\_alertas/boletines/2017/Farma-seguridad-Vol-6-N-1-Ene-Feb-2017.pdf](https://www.invima.gov.co/images/pdf/farmacovigilancia_alertas/boletines/2017/Farma-seguridad-Vol-6-N-1-Ene-Feb-2017.pdf)
7. Fundación Hospital Universitario San Vicente. Área Vigilancia Farmacológica HUSVF. Clasificación de problemas relacionados con medicamentos (PRM). Versión N.º 6 Medellín; p. 1-2.
8. República de Colombia. Ley 100 de 1993, por la cual se crea el sistema de seguridad social integral y se dictan otras disposiciones. *Diario Oficial*, N° 41.148, (23 de diciembre de 1993) [accessed 13/8/2017]. Available at: [http://www.comisionseptimasenado.gov.co/salud/salud en ley 100 de 1993.pdf](http://www.comisionseptimasenado.gov.co/salud/salud%20en%20ley%20100%20de%201993.pdf)
9. Sotoca Momblona JM, Canivell Fusté S, Alemany Vilches L, Sisó Almirall A, Codina Jané C, Ribas Sala J. Problemas relacionados con la medicación que causan ingresos hospitalarios. *Aten Primaria.* 2009;41(3):141-6.
10. Baena Parejo MI, Faus Dáder MJ, Marín Iglesias R, Zarzuelo Zurita A, Jiménez Martín J, Martínez Olmos J. Problemas de salud relacionados con los medicamentos en un servicio de urgencias hospitalario. *Med Clin (Barc)* [Internet]. 2005 [accessed 13/8/2017];124(7):250-5. Available at: <http://dx.doi.org/10.1157/13072035>
11. Gorgas Torner MQ, Odena Estradé E, Pastor Solernou F. Pharmaceutical care for drug-related problems in inpatients. *Farm Hosp.* 2003;27:280-9.
12. Pérez MDN, García AA, Urra JEC, Cebrián RG, Fernández MDI, Villar JL, *et al*. Análisis de los problemas, relacionados con medicamentos, detectados en un hospital general. *Rev Calid Asist* [Internet]. 2007 [accessed 13/8/2017];22(2):61-6. Available at: [http://dx.doi.org/10.1016/S1134-282X\(07\)1194-6](http://dx.doi.org/10.1016/S1134-282X(07)1194-6)
13. Otero-López MJ, Alonso-Hernández P, Maderuelo-Fernández JA, Garrido-Corro B, Domínguez-Gil A, Sánchez-Rodríguez A. Preventable adverse drug events in hospitalized patients. *Med Clin (Barc)* [Internet]. 2006 [accessed 13/8/2017];126(3):81-7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16472480>
14. Parody Rúa E, Segu Tolosa JL. Efectividad y estimación de costes en una intervención sobre problemas relacionados con los medicamentos en atención primaria. *Atención Primaria* [Internet]. 2005 [accessed 13/8/2017];35(9):472-7. Available at: <http://linkinghub.elsevier.com/retrieve/pii/S0212656705704030>
15. Alonso Hernández P, Otero López MJ, Maderuelo Fernández JA. Ingresos hospitalarios causados por medicamentos: Incidencia, características y coste. *Farm Hosp.* 2002;26(2):77-89.
16. Tuneu Valls I, García-Peláez M, López Sánchez S, Serra Soler G, Alba Aranda G, de Irala Indart C, *et al*. Drug related problems in patients who visit an emergency room. *Pharm Care Esp.* 2000;2:177-92.
17. Jameson JP, VanNoord GR. Pharmacotherapy Consultation on Polypharmacy Patients in Ambulatory Care. *Ann Pharmacother* [Internet]. 2001 [accessed 13/8/2017];35(7-8):835-40. Available at: <https://doi.org/10.1345/aph.10259>
18. Cubero-Caballero S, Torres-Murillo JM, Campos-Pérez MA, Gómez del Río S, Calleja-Hernández MÁ. Problemas relacionados con los medicamentos en el área de observación de urgencias de un hospital de tercer nivel. *Farm Hosp* [Internet]. 2006 [accessed 13/8/2017];30(3):187-92. Available at: [http://dx.doi.org/10.1016/S1130-6343\(06\)73970-8](http://dx.doi.org/10.1016/S1130-6343(06)73970-8)
19. Baena MI, Marín R, Martínez Olmos J, Fajardo P, Vargas J, Faus MJ. Nuevos criterios para determinar la evitabilidad de los problemas relacionados con los medicamentos. Una revisión actualizada a partir de la experiencia con 2558 personas [Internet]. *Pharm Care Esp.* 2002 [accessed 13/8/2017];4:393-6. Available at: <http://pharmaceutical-care.org/revista/doccontenidos/articulos/393396.pdf>
20. Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist. *Eur J Intern Med* [Internet]. 2015 [accessed 13/8/2017];26(6):399-406. Available at: <http://dx.doi.org/10.1016/j.ejim.2015.05.012>
21. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. *Arch Intern Med* [Internet]. 2003 [accessed 13/8/2017];163(17):2014-8. Available at: <http://dx.doi.org/10.1001/archinte.163.17.2014>
22. García NI, Jané CC, Creus MT, Dalmau LM, Vila RG, Sala JR. Evaluación de la integración del farmacéutico en equipos de atención de unidades de hospitalización. *Farm Hosp.* 2002;26(1):18-27.
23. García V, Marquina I, Olabarri A, Miranda G, Rubiera G, Baena MI. [Negative Results Associated With Medication in the Emergency Department of a Hospital]. *Farm Hosp* [Internet]. 2008 [accessed 13/8/2017];32(3):157-62. Available at: [http://dx.doi.org/10.1016/S2173-5085\(08\)70037-6](http://dx.doi.org/10.1016/S2173-5085(08)70037-6)